For most people with gout, allopurinol is a lifelong medication. Stopping it allows uric acid levels to climb back to where they were within weeks, which sets the stage for new flare-ups and further joint damage. The goal of treatment is not just to stop today’s symptoms but to gradually dissolve the uric acid crystals already deposited in your joints, a process that can take anywhere from a few months to several years depending on how long you have had the disease.
Why Allopurinol Is Not a Short Course
Allopurinol works by blocking xanthine oxidase, an enzyme your body uses to produce uric acid. While the drug is active, your uric acid level drops. But allopurinol does not fix the underlying reason your body overproduces or under-excretes uric acid in the first place. The moment you stop taking it, xanthine oxidase gets back to work and serum urate rebounds to pre-treatment levels, typically within a few weeks. Research confirms that this rebound can trigger recurrent gout flares if treatment is not restarted.
This makes allopurinol fundamentally different from, say, an antibiotic you take for ten days and then stop. Gout is a chronic metabolic condition, and allopurinol manages it the way blood pressure medication manages hypertension. You feel fine while you are on it precisely because it is working. Remove the drug and the problem comes back.
The Target You Are Aiming For
Modern gout guidelines follow a “treat-to-target” approach. The target is a serum urate level below about 6 mg/dL (0.36 mmol/L) for most people. Keeping urate below this threshold does two things: it prevents new uric acid crystals from forming, and it allows existing crystals to slowly dissolve back into the bloodstream so the kidneys can excrete them. Over the long term, this suppresses gout flares and shrinks tophi, the chalky deposits of uric acid that can form under the skin and around joints.
Reaching that target usually requires dose adjustments over time rather than staying on whatever dose you started with. Your doctor will check your uric acid level periodically and increase the dose until you are consistently below the threshold. How much allopurinol you need varies widely from person to person.
How Long Before the Crystals Are Actually Gone
Even once your uric acid is in the target range, the crystals that have already built up in your joints do not vanish overnight. A study that tracked crystal disappearance by examining joint fluid found that the time required for complete dissolution ranged from 3 months to 33 months after urate levels were brought to normal. The longer someone had been living with gout before treatment, the longer the crystals took to clear. Crystal counts did begin dropping within the first three months, but full resolution took considerably longer in people with longstanding disease.
This is an underappreciated point. Many people expect to feel better quickly after starting allopurinol, and when flares continue during the first several months, they assume the drug is not working. In reality, dissolving years of crystal buildup is a slow process, and flares during the early phase of treatment are common and expected.
The Rough First Months
Starting allopurinol can paradoxically trigger gout flares. As uric acid levels shift, existing crystal deposits become unstable and can provoke inflammation. This is why doctors typically prescribe a low starting dose and increase it gradually, a strategy called “start low, go slow.” Research into this approach found that people who began on a higher starting dose of 100 mg had over three times the odds of a flare in the first six months compared to those who started lower. Having a flare in the month before starting allopurinol also raised the risk substantially.
To cushion this transition, many doctors prescribe a low-dose anti-inflammatory medication alongside allopurinol for the first several months. Colchicine is the most commonly used option for this purpose, taken daily at a low dose to dampen flare activity while the allopurinol takes hold. The practice is widespread, and studies have examined whether colchicine truly reduces flare frequency and severity during allopurinol initiation.
An interesting wrinkle emerged from one trial: after colchicine prophylaxis was stopped at around six months, patients who had been on it actually had higher odds of flaring in the subsequent months compared to those who had been on placebo. The likely explanation is that colchicine was masking ongoing crystal activity, and once that anti-inflammatory shield was removed, the underlying instability became apparent. This reinforces the importance of achieving and maintaining the urate target rather than relying solely on anti-inflammatory cover.
What Happens If You Stop
People stop allopurinol for all sorts of reasons. Some feel fine and assume they no longer need it. Others experience side effects. Some never fully understood that it was meant to be permanent. A study of community-dwelling adults with gout catalogued the reasons for discontinuation and noted a key clinical reality: serum urate climbs back to pre-treatment levels within weeks of stopping, and gout flares are likely to return if the medication is not restarted.
The rebound is not gradual. Uric acid production ramps up quickly once the enzyme block is removed, and the newly elevated urate can crystallize in joints that had been slowly clearing. For people who have been on allopurinol long enough to dissolve most of their crystal burden, stopping means re-seeding those deposits and potentially starting the whole process over.
There is a small theoretical window in which stopping might be considered: if someone had very mild gout, has been at target for years, and has no tophi or joint damage. But even in this scenario, the evidence supporting discontinuation is thin, and most rheumatologists advise continuing treatment indefinitely rather than gambling on a relapse.
Kidney Function and Dose Decisions
Allopurinol is broken down into an active metabolite called oxypurinol, which is cleared by the kidneys. In people with reduced kidney function, oxypurinol builds up in the body, and there has been longstanding concern that this accumulation raises the risk of serious side effects. For decades, many prescribing guidelines recommended capping the allopurinol dose based on kidney function, which frequently meant people with kidney disease were stuck on doses too low to reach their urate target.
More recent evidence has pushed back on this practice. Clinical pharmacokinetic modeling and updated studies show that titrating allopurinol upward to reach the urate target is both safe and effective in people with impaired kidneys, and that arbitrarily restricting the dose based solely on kidney function often means patients never achieve adequate urate lowering. The key is to increase the dose gradually while monitoring for adverse reactions, not to impose a ceiling that guarantees treatment failure.
The Rare but Serious Allergic Reaction
The most feared side effect of allopurinol is a severe allergic reaction called allopurinol hypersensitivity syndrome, which can manifest as Stevens-Johnson syndrome or toxic epidermal necrolysis. These are rare but potentially fatal skin reactions. The risk is strongly linked to a genetic marker called HLA-B*5801. People who carry this variant have a dramatically higher chance of developing these reactions.
HLA-B*5801 is more common in certain populations, particularly people of Southeast Asian, Korean, and African American descent. Guidelines now recommend testing for this marker before starting allopurinol in high-risk groups. Cost-effectiveness analyses have shown that screening before prescribing is worthwhile in populations where the marker is prevalent. If you test positive, allopurinol should not be used, and an alternative urate-lowering drug like febuxostat is typically prescribed instead.
For people who test negative or who belong to low-prevalence populations, the risk of severe hypersensitivity is very low. Milder side effects like skin rash and gastrointestinal upset do occur but are usually manageable and do not require stopping the drug permanently.
A Dangerous Drug Interaction Worth Knowing About
One drug interaction with allopurinol is serious enough that anyone taking it should be aware of it. Azathioprine, an immunosuppressant used in organ transplant recipients and in certain autoimmune diseases, is metabolized in part by xanthine oxidase, the same enzyme allopurinol blocks. When the two drugs are taken together, azathioprine’s active metabolites accumulate to dangerous levels because allopurinol shuts down one of the main pathways the body uses to inactivate them. The result can be severe suppression of blood cell production. Case reports have documented profound drops in all blood cell lines in patients who were prescribed both drugs without appropriate dose adjustments.
If you are on azathioprine and need urate-lowering therapy, your doctor will either use a dramatically reduced azathioprine dose with careful blood monitoring or choose a different urate-lowering drug altogether. This is not a theoretical concern; it is a well-documented and potentially life-threatening interaction.
Sticking With It Is Harder Than It Sounds
Adherence to allopurinol is notoriously poor. A large national cohort study of U.S. veterans examined allopurinol adherence patterns and found that multiple factors influenced whether patients stayed on the drug. Older patients and those with more comorbidities were somewhat more likely to keep taking it. Patients who started on very high doses (above 300 mg per day) were less likely to stick with it compared to those who began at 100 mg or less, which adds another practical argument for the start-low approach beyond just flare prevention.
Racial and ethnic disparities in adherence were also apparent, with Black and Hispanic patients showing lower adherence rates even after accounting for other variables. Care setting mattered too: patients followed by a rheumatologist were more adherent than those managed by other providers. These findings underscore that long-term gout management is not just a pharmacology problem but a healthcare-system problem. Patients who understand why they are taking the drug, who have regular follow-up with urate monitoring, and who start on a tolerable dose are the ones most likely to stay on it.
Possible Heart Benefits
An interesting line of research suggests that allopurinol may do more than just lower uric acid. Observational studies have linked allopurinol use to reduced rates of stroke and heart attack, particularly in older adults with high blood pressure. One large study found that allopurinol use was associated with roughly half the risk of stroke and about 40% lower risk of cardiac events compared to non-users, with higher doses showing greater benefit. A separate study in patients with both gout and diabetes found that current allopurinol users had about a third lower risk of stroke or heart attack compared to former users who had stopped the drug.
These are observational findings, meaning they cannot prove that allopurinol itself is responsible for the benefit. People who stay on allopurinol tend to be more engaged with their healthcare in general, which introduces bias. Randomized trials have produced mixed results on the cardiovascular question, and the largest such trial did not confirm a clear cardiovascular benefit. Still, the signal is persistent enough across multiple studies that researchers continue to investigate it, and for gout patients who also have cardiovascular risk factors, the possibility of a dual benefit is at least a reasonable encouragement to stay on the medication.
What About High Uric Acid Without Gout Symptoms
A separate and more contentious question is whether allopurinol should be used for asymptomatic hyperuricemia, meaning elevated uric acid levels in someone who has never had a gout attack. This is surprisingly common; many people have high urate on blood tests without ever developing joint symptoms. A systematic review of randomized controlled trials addressing this question found broad inconsistency among the available studies. Designs and populations varied so much that the findings were difficult to generalize, and hard clinical endpoints like cardiovascular events or kidney outcomes were generally not assessed.
In most Western guidelines, the consensus is against treating asymptomatic hyperuricemia with allopurinol. The Japanese guidelines are an exception, taking a more permissive stance toward early treatment. If you have been told your uric acid is high but you have never had a gout flare, starting allopurinol is not a straightforward decision and would involve weighing uncertain long-term benefits against the commitment to a daily medication, possible side effects, and the cost of ongoing monitoring.
When an Alternative Makes More Sense
Allopurinol is the first-line urate-lowering drug in most guidelines, but it is not the only option. Febuxostat is another xanthine oxidase inhibitor that works by the same general mechanism but has a different chemical structure, making it suitable for people who cannot tolerate allopurinol or who carry the HLA-B*5801 marker. It tends to be more expensive, which is one reason allopurinol remains the default.
Probenecid takes a completely different approach. Instead of reducing uric acid production, it increases the amount excreted by the kidneys. It has been in use since the 1950s and is generally reserved for patients who cannot tolerate xanthine oxidase inhibitors or who do not reach their urate target with them alone. Probenecid requires adequate kidney function to work and is less effective in people with significant renal impairment. It also requires the patient to stay well hydrated, as pushing more uric acid through the kidneys raises the risk of kidney stones.
Regardless of which drug is chosen, the same principle applies: urate-lowering therapy for gout is a long-term commitment. Switching from allopurinol to an alternative does not change the duration of treatment, only the tool being used.
Practical Monitoring Over the Years
Once you are stable on allopurinol and consistently hitting your urate target, the monitoring schedule typically becomes less intensive. In the early phase, uric acid levels might be checked every few weeks to guide dose increases. After the target is reached, checks might drop to every six months or annually. Your doctor will also periodically check kidney function and liver enzymes, since allopurinol is metabolized by the liver and its metabolite cleared by the kidneys.
If your urate drifts above target at any point, the dose may need to be increased, or adherence may need to be revisited honestly. Lifestyle factors like weight gain, dietary changes, or new medications (especially diuretics, which raise uric acid) can shift the equation over time. Gout management is not static; it requires occasional recalibration even on a drug that is working well. The visits themselves serve another purpose beyond blood work. They are an opportunity to confirm that you are still tolerating the medication, to catch any emerging side effects early, and to reinforce why staying on treatment matters even when you feel perfectly fine.